RESUMEN
PURPOSE: SBRT (stereotactic body radiation therapy) is widely used as a curative treatment in tumoral lesions and has become a fundamental tool for the treatment of spine metastasis. In this study, we present survival and toxicity outcomes of spine SBRT after a 2-year follow-up. METHODS/PATIENTS: Data from spine SBRT treatments performed at our institution between March 2012 and February 2020 was collected. Medical records, including demographic, primary tumor, and treatment characteristics were reviewed. Patient follow-up included clinical evaluation, imaging, and blood tests. Toxicity was recorded according to CTCAE v4.0. RESULTS: We analyzed 73 consecutive spine SBRT treatments in 60 patients. 39.7% of the cases had primary breast cancer and 23.3% had prostate cancer. Most cases (87.7%) were treated with a single SBRT fraction of 16 Gy. Median follow-up was 26.1 months (range 1.7-78.6), and 1- and 2-year overall survival (OS) rates were 96.9% and 84.2%, respectively. Local control (LC) rates at 1- and 2-years were 76.3% and 70.6%, respectively. Multivariate analysis identified histology as a prognostic factor for both OS and LC. Patients who underwent spine SBRT 6 months after the spinal lesion diagnosis had LC at 2 years of 88%, vs 61.7% for those who underwent SBRT before this period. No grade III or higher toxicity was reported. The vertebral compression fracture (VCF) rate was 4.1%. CONCLUSION: Spine SBRT at our institution showed a 2-year LC of 70.6%, without G3 toxicities. Delaying SBRT at least 6 months to administer systemic treatment was related to an improvement in local control.
Asunto(s)
Radiocirugia , Neoplasias de la Columna Vertebral/radioterapia , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Radiocirugia/efectos adversos , Estudios Retrospectivos , Neoplasias de la Columna Vertebral/mortalidad , Neoplasias de la Columna Vertebral/secundario , Tasa de Supervivencia , Factores de Tiempo , Tiempo de Tratamiento , Resultado del TratamientoRESUMEN
INTRODUCTION: Colorectal cancer treatment requires a complex, multidisciplinary approach. Because of the potential variability, monitoring through clinical audits is advisable. This study assesses the effects of a quality improvement action plan in patients with locally advanced rectal cancer and treated with radiotherapy. METHODS: Comparative, multicentre study in two cohorts of 120 patients each, selected randomly from patients diagnosed with rectal cancer who had initiated radiotherapy with a curative intent. Based on the results from a baseline clinical audit in 2013, a quality improvement action plan was designed and implemented; a second audit in 2017 evaluated its impact. RESULTS: Standardised information was present on 77.5% of the magnetic resonance imaging (MRI) staging reports. Treatment strategies were similar in all three study centres. Of the patients whose treatment was interrupted, just 9.7% received a compensation dose. There was an increase in MRI re-staging from 32.5 to 61.5%, and a significant decrease in unreported circumferential resection margins following neoadjuvant therapy (ypCRM), from 34.5 to 5.6% (p < 0.001). CONCLUSIONS: The comparison between two clinical audits showed improvements in neoadjuvant radiotherapy in rectal cancer patients. Some indicators reveal areas in need of additional efforts, for example to reduce the overall treatment time.
Asunto(s)
Adenocarcinoma/radioterapia , Carcinoma de Células Escamosas/radioterapia , Atención a la Salud/normas , Terapia Neoadyuvante/mortalidad , Mejoramiento de la Calidad , Radioterapia Adyuvante/mortalidad , Neoplasias del Recto/radioterapia , Adenocarcinoma/patología , Anciano , Anciano de 80 o más Años , Carcinoma de Células Escamosas/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Neoplasias del Recto/patología , Tasa de SupervivenciaRESUMEN
Introducción y objetivo: El síndrome de retirada de abiraterona (SRA) se caracteriza por un descenso transitorio de PSA tras la discontinuación del tratamiento con acetato de abiraterona (AA) en los pacientes diagnosticados de cáncer de próstata resistente a castración metastásico (CPRCm). El objetivo de nuestro estudio es identificar posibles factores predictivos al diagnóstico que puedan influir en el SRA. Materiales y métodos: Se realizó un estudio retrospectivo de los pacientes que recibieron tratamiento con AA en el Institut Català d'Oncologia - L'Hospitalet entre 2015 y 2017, obteniendo una muestra de 70 pacientes. Resultados: Presentaron SRA 11 pacientes. La edad media al diagnóstico fue 65,73 años y la edad media de presentación 74,18 años. El número de ciclo de tratamiento fue el noveno. La mediana de PSA al diagnóstico fue de 30,5ng/ml; la mediana de PSA en el SRA, 33,24 ng/ml; y la mediana de PSA antes de iniciar otro tratamiento, 15,78 ng/ml. La media de seguimiento tras SRA fue de 8,2 meses. Los factores predictivos del SRA serían PSA elevado (p = 0,002), ISUP ≥ 4 (p = 0,002) y estadio IV al diagnóstico (p < 0,001). El estadio T presenta un riesgo elevado, pero sin significación estadística. Se obtuvo una ABC ROC de 0,84, con un IC 95% entre 0,77 y 0,92 (p < 0,001). Conclusiones: La incidencia del SRA no es despreciable, describiendo respuestas prolongadas tras la retirada del AA, incluso la posibilidad de una mejoría en la supervivencia global. Estos resultados podrían suponer un cambio en el esquema de tratamiento del CPRCm
Introduction and objective: Abiraterone withdrawal syndrome (AWS) is characterized by a transient decrease in the PSA after abiraterone acetate (AA) treatment discontinuation in patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). The aim of our study is to identify the possible predictive factors of AWS at diagnosis. Materials and methods: We performed a retrospective study of 70 patients treated with AA at the Institut Català d'Oncologia - L'Hospitalet between 2015 and 2017. Results: Eleven patients presented AWS. The mean age at diagnosis was 65.73 years and the mean age of presentation was 74.18 years. Patients were in the ninth treatment cycle. The median PSA was: 30.5 ng/ml at diagnosis, 33.24 ng/ml in the AWS, and 15.78 ng/ml before starting another treatment. The median follow-up period after AWS was 8.2 months. The predictive factors of AWS would be: high PSA (p = 0.002), ISUP ≥ 4 (p = 0.002) and stage IV at diagnosis (p<0.001). Patients with a T stage present high risk, but without statistical significance. An AUC of 0.84 was obtained, with a 95% CI between 0.77 and 0.92 (p < 0.001). Conclusions: The incidence of AWS is not negligible, describing prolonged responses after AA withdrawal, including the possibility of increased overall survival. These results could entail new treatment schemes for mCRPC
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Anciano , Acetato de Abiraterona/administración & dosificación , Antineoplásicos/administración & dosificación , Neoplasias de la Próstata/tratamiento farmacológico , Antígeno Prostático Específico/sangre , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Síndrome , Sensibilidad y EspecificidadRESUMEN
INTRODUCTION AND OBJECTIVE: Abiraterone withdrawal syndrome (AWS) is characterized by a transient decrease in the PSA after abiraterone acetate (AA) treatment discontinuation in patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). The aim of our study is to identify the possible predictive factors of AWS at diagnosis. MATERIALS AND METHODS: We performed a retrospective study of 70 patients treated with AA at the Institut Català d'Oncologia - L'Hospitalet between 2015 and 2017. RESULTS: 11 patients presented AWS. The mean age at diagnosis was 65.73 years and the mean age of presentation was 74.18 years. Patients were in the ninth treatment cycle. The median PSA was: 30.5ng/ml at diagnosis, 33.24ng/ml in the AWS, and 15.78ng/ml before starting another treatment. The median follow-up period after AWS was 8.2 months. The predictive factors of AWS would be: high PSA (p=.002), ISUP≥4 (p=.002) and stage IV at diagnosis (p<.001). Patients with a T stage present high risk, but without statistical significance. An AUC of 0.84 was obtained, with a 95% CI between 0.77 and 0.92 (p<.001). CONCLUSIONS: The incidence of AWS is not negligible, describing prolonged responses after AA withdrawal, including the possibility of increased overall survival. These results could entail new treatment schemes for mCRPC.
Asunto(s)
Acetato de Abiraterona/efectos adversos , Antineoplásicos/efectos adversos , Neoplasias de la Próstata Resistentes a la Castración/tratamiento farmacológico , Síndrome de Abstinencia a Sustancias/etiología , Anciano , Intervalos de Confianza , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata Resistentes a la Castración/sangre , Neoplasias de la Próstata Resistentes a la Castración/patología , Curva ROC , Estudios Retrospectivos , Síndrome de Abstinencia a Sustancias/sangreRESUMEN
BACKGROUND: The therapeutic approach to cancer is complex and multidisciplinary. Radiotherapy is among the essential treatments, whether used alone or in conjunction with other therapies. This study reports a clinical audit of the radiotherapy process to assess the process of care, evaluate adherence to agreed protocols and measure the variability to improve therapeutic quality for rectal cancer. METHODS: Multicentre retrospective cohort study in a representative sample of patients diagnosed with rectal cancer in the Institut Català d'Oncologia, a comprehensive cancer centre with three different settings. We developed a set of indicators to assess the key areas of the radiotherapy process. The clinical audit consisted of a review of a random sample of 40 clinical histories for each centre. RESULTS: The demographic profile, histology and staging of patients were similar between centres. The MRI reports did not include the distance from tumour to mesorectal fascia (rCRM) in 38.3% of the cases. 96.7% of patients received the planned dose, and 57.4% received it at the planned time. Surgery followed neoadjuvant treatment in 96.7% of the patients. Among this group, postoperative CRM was recorded in 65.5% of the cases and was negative in 93.4% of these. With regard to the 34.5% (n = 40) of cases where no CRM value was stated, there were differences between the centres. Mean follow-up was 3.4 (SD 0.6) years, and overall survival at four years was 81.7%. CONCLUSIONS: The audit revealed a suboptimal degree of adherence to clinical practice guidelines. Significant variability between centres exists from a clinical perspective but especially with regard to organization and process.
RESUMEN
BACKGROUND: Novel predictors of prognosis and treatment response for prostate cancer (PCa) are required to better individualize treatment. Single-nucleotide polymorphisms (SNPs) in four genes directly (XRCC5 (X-ray repair complementing defective repair in Chinese hamster cells 5) and XRCC6 (X-ray repair complementing defective repair in Chinese hamster cells 6)) or indirectly (PARP1 and major vault protein (MVP)) involved in non-homologous end joining were examined in 494 Spanish PCa patients. METHODS: A total of 22 SNPs were genotyped in a Biotrove OpenArray NT Cycler. Clinical tumor stage, diagnostic PSA serum levels and Gleason score at diagnosis were obtained for all participants. Genotypic and allelic frequencies were determined using the web-based environment SNPator. RESULTS: (XRCC6) rs2267437 appeared as a risk factor for developing more aggressive PCa tumors. Those patients carrying the GG genotype were at higher risk of developing bigger tumors (odds ratio (OR)=2.04, 95% confidence interval (CI) 1.26-3.29, P=0.004), present higher diagnostic PSA levels (OR=2.12, 95% CI 1.19-3.78, P=0.011), higher Gleason score (OR=1.65, 95% CI 1.01-2.68, P=0.044) and D'Amico higher risk tumors (OR=2.38, 95% CI 1.24-4.58, P=0.009) than those patients carrying the CC/CG genotypes. Those patients carrying the (MVP) rs3815824 TT genotype were at higher risk of presenting higher diagnostic PSA levels (OR=4.74, 95% CI 1.40-16.07, P=0.013) than those patients carrying the CC genotype. When both SNPs were analyzed in combination, those patients carrying the risk genotypes were at higher risk of developing D'Amico higher risk tumors (OR=3.33, 95% CI 1.56-7.17, P=0.002). CONCLUSIONS: We believe that for the first time, genetic variants at XRCC6 and MVP genes are associated with risk of more aggressive disease, and would be taken into account when assessing the malignancy of PCa.
Asunto(s)
Antígenos Nucleares/genética , Proteínas de Unión al ADN/genética , Estudios de Asociación Genética , Neoplasias de la Próstata/genética , Partículas Ribonucleoproteicas en Bóveda/genética , Roturas del ADN de Doble Cadena , ADN Helicasas/genética , Reparación del ADN/genética , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Autoantígeno Ku , Masculino , Clasificación del Tumor , Estadificación de Neoplasias , Poli(ADP-Ribosa) Polimerasa-1 , Poli(ADP-Ribosa) Polimerasas/genética , Polimorfismo de Nucleótido Simple , Neoplasias de la Próstata/patología , Factores de RiesgoRESUMEN
Brachytherapy has come a long way from its beginnings nearly a century ago. In recent years, brachytherapy has become ever more sophisticated thanks to a multitude of technological developments, including high-dose rate afterloading machines, image-guidance, and advanced planning systems. One of the advantages of brachytherapy, apart from the well-known capability of delivering highly conformal doses directly to the target, is that it is highly adaptable and can be used as a primary, adjunct, or salvage treatment. However, despite the existence of international treatment guidelines, the clinical practice of brachytherapy varies greatly by region, country, and even institution. In the present article, we provide an overview of recent findings from the Patterns of Care for Brachytherapy in Europe (PCBE) Study and we discuss new technologies used in brachytherapy and the emerging concept of "new biology" that supports the use of high-dose brachytherapy. Compared to the 1990s, the use of brachytherapy has increased substantially and it is expected to continue growing in the future as it becomes ever more precise and efficient.
Asunto(s)
Braquiterapia/tendencias , Neoplasias/radioterapia , Guías de Práctica Clínica como Asunto , Braquiterapia/instrumentación , Braquiterapia/métodos , Braquiterapia/normas , Braquiterapia/estadística & datos numéricos , Efecto Espectador , Fraccionamiento de la Dosis de Radiación , Europa (Continente) , Humanos , Cuidados Intraoperatorios , Neoplasias/cirugía , Órganos en Riesgo , Formulación de Políticas , Pautas de la Práctica en Medicina/estadística & datos numéricos , Oncología por Radiación/estadística & datos numéricos , Radiocirugia , Dosificación Radioterapéutica , Radioterapia Guiada por Imagen , Transducción de Señal/efectos de la radiación , Encuestas y CuestionariosRESUMEN
INTRODUCTION: The aim of this study is to determine the interobserver variability (IV) between radiation oncologists (RO) in target volume delineation for postoperative gastric cancer (GC) radiotherapy planning. MATERIALS AND METHODS: Four physicians were asked to delimitate clinical target volume (CTV) on the same 3D CT images in 9 postoperative radiochemotherapy GC patients. Instructions were given to include tumour bed, remaining stomach, anastomosis, duodenal loop and local lymph nodes. The principal variable was spatial volume discrepancy between the main observer (called "A") and other observers (all called "B"), which were compared using the mathematical formula A⌣B/A⌢B, applied to the 3D CT images using Boolean operators. Analysis of variance with two random effects (observers and patients) was performed. RESULTS: Mean volumes were 1410 cm(3) for OBA, 1231 cm(3) for OB2, 734.6 cm(3) for OB3 and 1350 cm(3) for OB4. Discrepancies were 519.9±431.6 cm(3) for OB2, 652.1±294.36 cm(3) for OB3 and 225.90±237.07 cm(3) for OB4. Standard deviation ascribed to patients as random effect was 898.6 cm(3) and that ascribed to observers was 198.10 cm(3), considered as a statistically significant difference. CONCLUSIONS: A significant IV in target delineation that can be attributed to many factors depends more on patients' characteristics than RO delineating decisions (AU)
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Oncología por Radiación/métodos , Oncología por Radiación/tendencias , Planificación de la Radioterapia Asistida por Computador/instrumentación , Planificación de la Radioterapia Asistida por Computador/métodos , Neoplasias Gástricas , Neoplasias Gástricas/terapia , Quimioradioterapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Leucovorina/administración & dosificación , Recurrencia Local de Neoplasia , Recurrencia Local de Neoplasia/terapia , Estudios Prospectivos , Tomografía Computarizada por Rayos XRESUMEN
OBJECTIVE: The aim of this follow-up pattern of care study was to evaluate current clinical practices, staffing and equipment, and to compare these results to a study performed 5 years previously. MATERIALS AND METHODS: This descriptive, pattern of care study was carried out via an online questionnaire. The survey was sent to a total of 95 cancer care centres in Spain. RESULTS: Seventy-three centres (76.8%) responded to the survey. More than half (57.5%) of responding centres offered brachytherapy (BT). A mean of 120 patients/centre were treated by BT in 2007. The most common localisations were the endometrium (29.6% of cases), prostate (29.6%), cervix uteri (14.6%), breast (12.6%), head and neck (3.6%) and vagina (2.5%). Other sites accounted for less than 2% of cases each. Most centres that offered BT (33/40 = 82.5%) were equipped with a dedicated BT operating room. The most commonly reported dosimetric method was CT dosimetry (31 of 40 centres = 77.5%), followed by plain film (30/40 = 75%), ultrasound (26/40 = 65%), MRI (8/40 = 20%), in vivo (7/40 = 17.5%) and PET-CT (5/40 = 12.5%) dosimetry. CONCLUSION: The three most common treatment sites (gynaecological, breast and prostate) remain unchanged from 2002, with prostate treatments showing large increase. Advanced dosimetric techniques (MRI, PET-CT and CT-dosimetry) continue to gain adherents. Some centres treat small numbers of patients, a finding that deserves more attention in terms of cost and quality of care. Although BT remains strong in Spain, it could be further strengthened by making modern dosimetric techniques and treatments more widely available (AU)
Asunto(s)
Humanos , Masculino , Femenino , Braquiterapia/instrumentación , Braquiterapia/tendencias , Braquiterapia , Neoplasias/radioterapia , Admisión y Programación de Personal , Pautas de la Práctica en Medicina , Estudios de Seguimiento , Neoplasias/patología , Neoplasias , Pronóstico , Encuestas y Cuestionarios/normas , Encuestas y Cuestionarios , Encuestas de Atención de la SaludAsunto(s)
Humanos , Masculino , Femenino , Oncología Médica/métodos , Oncología Médica/tendencias , Oncología por Radiación/educación , Oncología por Radiación/tendencias , Sociedades Médicas/organización & administración , Sociedades Médicas/tendencias , Terapia Combinada , Educación Médica Continua , Difusión de la Información/métodos , Comunicación Interdisciplinaria , Oncología por Radiación/métodos , Oncología por Radiación/organización & administración , Radioterapia/instrumentación , Radioterapia/métodos , Radioterapia/tendencias , España/epidemiologíaAsunto(s)
Oncología por Radiación/tendencias , Terapia Combinada , Educación Médica Continua , Humanos , Difusión de la Información/métodos , Comunicación Interdisciplinaria , Oncología Médica/métodos , Oncología Médica/tendencias , Edición , Oncología por Radiación/educación , Oncología por Radiación/métodos , Oncología por Radiación/organización & administración , Radioterapia/instrumentación , Radioterapia/métodos , Radioterapia/tendencias , Sociedades Médicas , EspañaRESUMEN
OBJECTIVES: The aim of this study was to retrospectively evaluate clinical characteristics, local control, acute and late toxicity, and prognostic factors of patients with anal canal carcinoma treated with brachytherapy. METHODS: From 1989 to 2009, 38 patients were treated with iridium 192 low-dose-rate (N = 26) or pulsed-dose-rate (N = 12) interstitial brachytherapy at a single institution. The median age was 62 years (range, 38-86 years). The TNM classification was as follows: 10 T1, 22 T2, 5 T3 and 1 T4; 32 N0, 3 N1 and 3 N2. Most patients (32/38) received either a first course of radiochemotherapy (N = 22) or radiotherapy alone (N=10) consisting of a total delivered dose of 45 Gy to the pelvis (range, 32-50) followed by a boost a median of 18 days later of 15-35 Gy (median 20 Gy) to the anal canal. The remaining 6 cases were treated with brachytherapy alone (dose range, 60-65 Gy). RESULTS: With a median follow-up of 30 months (range, 4-200), 2- and 5-year local control rates were 91% and 87%, respectively. Preservation of the anal sphincter was achieved in 32 patients (84%). Three patients experienced incontinence after brachytherapy. Only 2 patients showed chronic mucositis grade 3/4. Age proved to be a statistically significant prognostic factor for overall survival in the univariate (p = 0.033) and multivariate analyses (p = 0.018). Concurrent chemotherapy with external beam radiotherapy was a statistically significant prognostic factor for disease-free survival in the univariate and multivariate analyses (p = 0.007 and p = 0.044, respectively). CONCLUSIONS: Interstitial brachytherapy appears to be an effective and well tolerated treatment for anal carcinoma offering both high local tumour control and anal sphincter preservation (AU)
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Neoplasias del Ano/radioterapia , Braquiterapia , Carcinoma de Células Escamosas/radioterapia , Radioisótopos de Iridio/uso terapéutico , Neoplasias Pulmonares/radioterapia , Canal Anal/patología , Neoplasias del Ano/patología , Carcinoma de Células Escamosas/secundario , Estudios de Seguimiento , Neoplasias Pulmonares/secundario , Estudios Retrospectivos , Tasa de Supervivencia , Factores de Tiempo , Resultado del TratamientoRESUMEN
The White Book of Radiation Oncology provides a comprehensive overview of the current state of the speciality of radiation oncology in Spain and is intended to be used as a reference for physicians, health care administrators and hospital managers. The present paper summarises the most relevant aspects of the book's 13 chapters in order to bring the message to a wider audience. Among the topics discussed are the epidemiology of cancer in Spain, the role of the radiation oncologist in cancer care, human and material resource needs, new technologies, training of specialists, clinical and cost management, clinical practice, quality control, radiological protection, ethics, relevant legislation, research & development, the history of radiation oncology in Spain and the origins of the Spanish Society of Radiation Oncology (SEOR) (AU)
Asunto(s)
Humanos , Masculino , Femenino , Oncología por Radiación/educación , Oncología por Radiación/organización & administración , Obras Médicas de Referencia , Oncología Médica/métodos , Oncología por Radiación , Oncología por Radiación/métodosAsunto(s)
Humanos , Neoplasias/radioterapia , Rol del Médico , Oncología por Radiación/métodos , Oncología por Radiación/tendencias , Medicina Interna/métodos , Medicina Interna/tendencias , Neoplasias/diagnóstico , Oncología por Radiación/instrumentación , Oncología por Radiación , Oncología por Radiación/organización & administraciónRESUMEN
The goal of this paper is to expose the clinical results and review of the literature of the treatment of spinal metastases with Stereotactic Body Radiation Therapy (SBRT) presenting one case. A spinal metastases from rectal cancer treated with a single dose of 18Gy is presented. The following physics aspects are exposed: Treatment volume, tumor volume marginal doses and maximum doses in organs at risk. Clinical and radiographic follow up is presented. Local control and pain relief after one year of follow up was excellent. In properly selected patients, the treatment of limited metastatic disease with SBRT appears to be feasible and safe (AU)